The Cognitive Neuroscience Journal

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Opinion Article - The Cognitive Neuroscience Journal (2024) Volume 7, Issue 6

The Role of Neural Networks in Cognitive Disorders: From Dysfunction to Therapeutic Targets

Matthew Wu *

Department of Neuroscience, University of Montréal, Canada

*Corresponding Author:
Matthew Wu
Department of Neuroscience, University of Montréal, Canada
E-mail: matthew.wu@umontreal.ca

Received: 2-Dec-2024, Manuscript No. aacnj-24-153681; Editor assigned: 4-Dec-2024, PreQC No. aacnj-24-153681 (PQ) Reviewed:17-Dec-2024, QC No. aacnj-24-153681 Revised:24-Dec-2024, Manuscript No. aacnj-24-153681; Published:30-Dec-2024, DOI: 10.35841/aacnj- 7.6.245

Citation: Wu M. The role of neural networks in cognitive disorders: From dysfunction to therapeutic Targets. J Cogn Neurosci. 2024;7(6):245

Visit for more related articles at The Cognitive Neuroscience Journal

Introduction

Cognitive disorders, encompassing a wide range of conditions such as Alzheimer's disease, Parkinson's disease, and schizophrenia, are often marked by impairments in memory, attention, reasoning, and executive functions. The brain's neural networks, responsible for processing and integrating information, are significantly disrupted in these conditions. Understanding the intricate role of these neural circuits in cognitive dysfunction has opened new avenues for therapeutic interventions. In this article, we explore the relationship between neural networks and cognitive disorders, from the mechanisms underlying dysfunction to potential therapeutic strategies [1].

Neural networks are complex, interconnected systems of neurons that communicate via electrical signals and synaptic connections. These networks are crucial for all cognitive processes, including perception, decision-making, and memory. Broadly, neural networks are categorized into large-scale brain networks, such as the default mode network (DMN), the fronto-parietal network, and the salience network, each playing specific roles in cognition. Disruptions in these networks are often linked to various cognitive disorders [2].

In Alzheimer's disease (AD), one of the most common forms of dementia, there is progressive degeneration of neurons in areas of the brain involved in memory and higher cognitive functions, such as the hippocampus and cortex. Research has shown that AD causes significant disruption in the communication between brain networks, particularly the DMN. This breakdown impairs memory consolidation, attention, and problem-solving abilities, hallmark symptoms of cognitive decline [3].

Parkinson’s disease (PD) is primarily characterized by motor dysfunction due to the degeneration of dopaminergic neurons in the basal ganglia. However, cognitive dysfunction is also a significant aspect of PD, often manifesting as deficits in attention, memory, and executive function. The basal ganglia, which are integral to motor control, are also critical for cognitive processes. Disruption in the basal ganglia-thalamo-cortical circuits has been implicated in the cognitive symptoms of PD, highlighting the importance of these networks in maintaining cognitive integrity [4].

Schizophrenia is a complex psychiatric disorder that affects various cognitive functions, including working memory, attention, and executive function. Research suggests that disruptions in the connectivity of neural networks, particularly between the prefrontal cortex and other brain regions, contribute to the cognitive impairments seen in schizophrenia. Abnormalities in the brain’s synaptic pruning processes and neurotransmitter imbalances further exacerbate network dysfunction, leading to the cognitive deficits that characterize the disorder [5].

The default mode network (DMN), which is active during rest and internal thought processes, plays a crucial role in self-referential thinking, memory retrieval, and social cognition. In many cognitive disorders, such as AD and schizophrenia, the DMN shows altered connectivity and activity patterns. In AD, for example, reduced DMN activity is associated with the early stages of memory decline. Understanding how the DMN functions in health and disease can offer insights into potential therapeutic targets for restoring cognitive function [6].

Brain plasticity, or neuroplasticity, refers to the brain’s ability to reorganize and form new neural connections in response to learning and injury. In cognitive disorders, neural plasticity is often impaired, exacerbating cognitive decline. In Alzheimer's and Parkinson's diseases, for example, the brain's ability to form new connections between neurons is hindered, preventing the compensation for lost functions. Restoring plasticity in these neural networks could be a promising therapeutic strategy for improving cognitive function in affected individuals [7].

Cognitive rehabilitation therapies (CRT) aim to enhance brain function by stimulating neural networks through structured cognitive exercises. These therapies are based on the principle of neuroplasticity, where repeated practice of cognitive tasks can strengthen neural circuits and improve brain connectivity. In patients with Alzheimer's disease, CRT has shown promise in slowing cognitive decline and improving quality of life. Tailoring these therapies to target specific neural networks may improve their efficacy and provide more personalized treatment options [8].

Pharmacological treatments have long been used to address symptoms of cognitive disorders, primarily by targeting neurotransmitter systems involved in neural communication. For instance, cholinesterase inhibitors in Alzheimer's disease enhance acetylcholine signaling to improve memory function. Similarly, dopaminergic drugs in Parkinson’s disease aim to restore dopamine activity and improve motor and cognitive symptoms. However, emerging therapies aim not only to modulate neurotransmitter activity but also to target the underlying network dysfunction that causes cognitive impairments [9].

Non-invasive brain stimulation (NIBS) techniques, such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), have shown promise in modulating neural network activity. These techniques involve applying magnetic or electrical fields to specific brain regions to enhance or inhibit neural activity. Studies have suggested that NIBS can improve cognitive function in patients with Alzheimer's disease, Parkinson’s disease, and schizophrenia by restoring disrupted neural network activity. Ongoing research is focused on optimizing these techniques for better outcomes [10].

Conclusion

The role of neural networks in cognitive disorders is both intricate and profound. Disruptions in network connectivity and activity contribute to the cognitive impairments seen in conditions like Alzheimer's disease, Parkinson's disease, and schizophrenia. By targeting these neural circuits through innovative therapies such as cognitive rehabilitation, pharmacological treatments, and non-invasive brain stimulation, researchers and clinicians are opening new doors for improving cognitive function and quality of life for patients. Understanding and addressing the network dysfunction at the heart of cognitive disorders represents a promising frontier in neuroscience and therapeutic intervention.

References

  1. Millan MJ, Agid Y, Brüne M, et al. Cognitive dysfunction in psychiatric disorders: Characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012;11(2):141-68.

    2. Indexed at, Google Scholar, Cross Ref

  2. Komatsu H, Watanabe E, Fukuchi M. Psychiatric neural networks and precision therapeutics by machine learning. Biomedicines. 2021;9(4):403.

    3. Indexed at, Google Scholar, Cross Ref

  3. Faingold C, Blumenfeld H, editors. Neuronal networks in brain function, CNS disorders, and therapeutics. Academic Press; 2013.

    4. Indexed at, Google Scholar, Cross Ref

  4. Xu MY, Wong AH. GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. Acta Pharmacologica Sinica. 2018;39(5):733-53.

    5. Indexed at, Google Scholar, Cross Ref

  5. Palop JJ, Mucke L. Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: From synapses toward neural networks. Nat Neurosci. 2010;13(7):812-8.

    6. Indexed at, Google Scholar, Cross Ref

  6. Escobar I, Xu J, Jackson CW, et al. Altered neural networks in the Papez circuit: Implications for cognitive dysfunction after cerebral ischemia. J Alzheimers Dis. 2019;67(2):425-46.

    7. Indexed at, Google Scholar, Cross Ref

  7. Peña-Ortega F. Amyloid beta?protein and neural network dysfunction. J Neurodegener Dis. 2013;2013(1):657470.

    8. Indexed at, Google Scholar, Cross Ref

  8. Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci. 2012;109(42):E2895-903.

    9. Indexed at, Google Scholar, Cross Ref

  9. Dineley KT, Pandya AA, Yakel JL. Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci. 2015;36(2):96-108.

    10. Indexed at, Google Scholar, Cross Ref

  10. Pan Z, Park C, Brietzke E, et al. Cognitive impairment in major depressive disorder. CNS spectrums. 2019 Feb;24(1):22-9.

    11. Indexed at, Google Scholar, Cross Ref

Get the App